1.0Lebanon News Gazettehttps://lebanonnewsgazette.comlnadminhttps://lebanonnewsgazette.com/author/lnadmin/Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women – Findings from HPTN 084 Study - Lebanon News Gazetterich600338<blockquote class="wp-embedded-content" data-secret="0QpGR9zyFV"><a href="https://lebanonnewsgazette.com/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study/">Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women – Findings from HPTN 084 Study</a></blockquote><iframe sandbox="allow-scripts" security="restricted" src="https://lebanonnewsgazette.com/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study/embed/#?secret=0QpGR9zyFV" width="600" height="338" title="“Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women – Findings from HPTN 084 Study” — Lebanon News Gazette" data-secret="0QpGR9zyFV" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"></iframe><script> /*! This file is auto-generated */ !function(d,l){"use strict";l.querySelector&&d.addEventListener&&"undefined"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i<o.length;i++)o[i].style.display="none";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute("style"),"height"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):"link"===t.message&&(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document); </script> DURHAM, N.C., July 28, 2022 (GLOBE NEWSWIRE) — Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November […]https://ci5.googleusercontent.com/proxy/c2SC14aYcNlQCtlHxw5c0-mkDuTu2Ed5hHe4yQmWkVxUArCqu2VZfPmgZ0KL3_XN80eBIv_C8Xqr0WvVIHLeaFOLCBIwEZf6sIk9QFom2zZKO-IjR_rjp4uEHgYHKjQ7=s0-d-e1-ft#https://www.globenewswire.com/newsroom/ti?nf=ODYwNzExMSM1MDYwNzEwIzIxOTc2NjY=